pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Recruiting

Phase 2

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerpBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Sponsor:

Michael K. Gibson

Code:

NCT05799144

Conditions

Metastatic Oropharyngeal Carcinoma

Recurrent Oropharyngeal Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

DNA Vaccine

Human Papillomavirus Tumor Antigen Vaccine

Pembrolizumab

Computed Tomography (CT)

Magnetic Resonance Imaging (MRI)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-30. This information was provided to ClinicalTrials.gov by Michael K. Gibson on 2024-06-21.